ArticleNature metabolism2024
From NAFLD to MASLD: implications of the new nomenclature for preclinical and clinical research.
Abstract read
In one paragraph
Article in Nature metabolism, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 67 papers, 6 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
67citing papers in PubMed, 6 pooled it
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
67 citing papers in PubMed, 6 syntheses or guidelines pooled it.
- Applications of machine learning in the diagnosis of non-alcoholic fatty liver disease: a systematic review and meta-analysis.BMC gastroenterology · 2026Pooled it
- Efficacy and safety of GLP-1 receptor agonists in patients with metabolic-associated fatty liver diseases: an umbrella review.Frontiers in medicine · 2026Pooled it
- Pooled it
- Exploring the Role of Extra Virgin Olive Oil (EVOO) in MASLD: Evidence from Human Consumption.Nutrients · 2025Pooled it
- Effect of SGLT2 inhibitors on liver fat content: A meta-analysis.Biomolecules & biomedicine · 2025Pooled it
- Traditional Chinese medicine for non-alcoholic fatty liver disease: an overview of systematic reviews with evidence mapping and metabolic outcome assessment.Frontiers in pharmacology · 2025Pooled it
- Ovarian tumor domain-containing protein 1 deficiency attenuates metabolic dysfunction-associated steatotic liver disease by promoting the ubiquitination of HSP90α in hepatocytes.Molecular biomedicine · 2026Article
- Observational
- Article
- HFpEF and MASLD: converging mechanisms and clinical implications.Nature reviews. Cardiology · 2026Review
- Prevalence and associated factors of liver fibrosis and steatosis in Gansu, China: a community-based cross-sectional study.BMC public health · 2026Article
- Hepatocyte PIEZO1 Negatively Regulates Lipogenesis and Ameliorates MASLD by Sensing Membrane Tension and Activating AMPK.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Sleep deprivation drives hepatic steatosis via sympathetic sprouting-induced ER stress in young male mice.JHEP reports : innovation in hepatology · 2026Article
- Steatosis index: a novel multiparametric ultrasound approach for accurate liver steatosis quantification and grading.Journal of gastroenterology · 2026Article
- Curcumin ameliorates metabolic dysfunction-associated steatotic liver diseaseActa pharmaceutica Sinica. B · 2026Article
- Review
- Pilot study of epigenetic aging and treatment response to semaglutide in the SLIM LIVER study.npj aging · 2026Article
- Article
- The Metabolic Dysfunction-Associated Steatotic Liver Disease-CKD Axis: Intersecting Pathways and Opportunities for Early Intervention.Kidney international reports · 2026Review
- The depletion of serine beta-lactamase-like protein (LACTB) ameliorates metabolic dysfunction-associated steatotic liver disease by reducing ubiquitin-mediated degradation of carnitine palmitoyltransferase 2.Diabetes, obesity & metabolism · 2026Article
7 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Cynthia L HsuDivision of Gastroenterology and Hepatology, Department of Medicine, University of California at San Diego, La Jolla, CA, USA.ORCID http://orcid.org/0000-0002-2604-1340
Rohit LoombaDivision of Gastroenterology and Hepatology, Department of Medicine, University of California at San Diego, La Jolla, CA, USA. roloomba@ucsd.edu.ORCID http://orcid.org/0000-0002-4845-9991
Funding
UC San Diego Clinical and Translational Research InstituteUL1TR001442 · NCATS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI FIRESTEIN, GARY S, HOGARTH, MICHAEL · 2015 to 2024
$88.3MYeast Genetics and Stress Response Genes-BiomedicalP42ES010337 · NIEHS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI TUKEY, ROBERT H · 2000 to 2022
$69.8MThe Southernearch Center for ALPD and CirrhosisP50AA011999 · NIAAA · UNIVERSITY OF SOUTHERN CALIFORNIA · PI HIDEKAZU TSUKAMOTO · 1999 to 2026
$45.8MPediatric Trials in Non-Alcoholic Steatohepatitis (NASH)U01DK061734 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI ROHIT LOOMBA · 2002 to 2026
$24.4MTissue-specific roles of FXR in CVD and NASHP01HL147835 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI LOOMBA, ROHIT · 2020 to 2024
$12.2MSan Diego Digestive Diseases Research CenterP30DK120515 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Bernd G. Schnabl · 2019 to 2026
$10.8MHIV MASLD Clinical Research Network (HCRN)R01DK121378 · NIDDK · INDIANA UNIVERSITY INDIANAPOLIS · PI NAGA P CHALASANI, ROHIT LOOMBA · 2020 to 2026
$8.7MQUS Technology for Diagnosis and Grading of Hepatic Steatosis in NAFLDR01DK106419 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI LOOMBA, ROHIT, SIRLIN, CLAUDE B · 2015 to 2019
$3.4MSan Diego Cirrhosis Clinical Research NetworkU01DK130190 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI ROHIT LOOMBA · 2021 to 2026
$2.3MNon-invasive screening of diabetics for advanced fibrosis due to NAFLDR01DK124318 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI LOOMBA, ROHIT · 2020 to 2022
$1.7MLinking Personality and SES Influences on Lifespan HealthK08AG031328 · NIA · UNIVERSITY OF ROCHESTER · PI CHAPMAN, BENJAMIN P · 2008 to 2012
$623kRole of gut microbial ethanol production in alcohol use disorder and alcohol-associated liver diseaseK99AA031328 · NIAAA · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI HSU, CYNTHIA LI-SHIN · 2023 to 2024
$351kAmerican Association for the Study of Liver Diseases (AASLD) CTORA23-208366NCATS NIH HHS UL1 TR001442NHLBI NIH HHS P01 HL147835NIAAA NIH HHS K99 AA031328NIAAA NIH HHS P50 AA011999NIDDK NIH HHS P30 DK120515NIDDK NIH HHS R01 DK106419NIDDK NIH HHS R01 DK121378NIDDK NIH HHS R01 DK124318NIDDK NIH HHS U01 DK061734NIDDK NIH HHS U01 DK130190NIEHS NIH HHS P42 ES010337U.S. Department of Health & Human Services | NIH | National Center for Advancing Translational Sciences (NCATS) 5UL1TR001442U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute (NHLBI) P01HL147835U.S. Department of Health & Human Services | NIH | National Institute of Environmental Health Sciences (NIEHS) 5P42ES010337U.S. Department of Health & Human Services | NIH | National Institute on Alcohol Abuse and Alcoholism (NIAAA) K99AA031328U.S. Department of Health & Human Services | NIH | National Institute on Alcohol Abuse and Alcoholism (NIAAA) P50AA011999
Abstract
PubMed holds no abstract for this paper.
Indexed as
Non-alcoholic Fatty Liver DiseaseTerminology as TopicAnimalsBiomedical ResearchHumans
Identifiers
What Socratic holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.